What are the indications, dosing regimen, contraindications, and monitoring recommendations for spironolactone in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Spironolactone: Clinical Guide

Spironolactone is a potassium-sparing diuretic and aldosterone antagonist with proven mortality benefit in heart failure with reduced ejection fraction (HFrEF) and established efficacy in primary aldosteronism, resistant hypertension, and acne in women.

Primary Indications

Heart Failure with Reduced Ejection Fraction (HFrEF)

Spironolactone is a foundational therapy for HFrEF patients with LVEF ≤35% and NYHA class II-IV symptoms, reducing both mortality and hospitalizations 1, 2, 3. The landmark RALES trial demonstrated a 30% relative risk reduction in death and 35% reduction in heart failure hospitalizations 1.

Patient Selection Criteria:

  • LVEF ≤35%
  • NYHA class II-IV symptoms (class II patients require prior cardiovascular hospitalization or elevated natriuretic peptides)
  • Already on optimal beta-blocker and ACE inhibitor or ARB therapy
  • Serum potassium <5.0 mEq/L
  • Creatinine ≤2.5 mg/dL in men or ≤2.0 mg/dL in women (eGFR >30 mL/min/1.73 m²) 2

Primary Aldosteronism

For patients with confirmed primary aldosteronism who are not surgical candidates or prefer medical management, spironolactone is first-line therapy 4, 5. Doses of 25-50 mg daily effectively control blood pressure in most patients, with lower doses (25-50 mg) reducing side effects while maintaining efficacy 4, 6.

Resistant Hypertension

Spironolactone produces average blood pressure reductions of 22/10 mmHg when added to existing antihypertensive regimens in resistant hypertension 7.

Acne in Women

For women with acne, spironolactone at 100 mg daily is an effective antibiotic-sparing option 8. This dose provides optimal efficacy with acceptable side effects, though doses up to 200 mg daily can be used if needed. Treatment requires several months to reach full effectiveness 8.

Dosing Regimens

Heart Failure

Starting dose: 25 mg once daily (or 12.5-25 mg for those with marginal renal function, eGFR 30-49 mL/min/1.73 m²) 1, 2, 9

Titration schedule:

  • Check potassium and renal function at 1 and 4 weeks after initiation
  • If tolerated, increase to 50 mg once daily after 4-8 weeks
  • Recheck potassium and renal function at 1 and 4 weeks after dose increase
  • Once at maintenance dose, monitor at 1,2,3, and 6 months, then every 6 months 1

Target dose: 50 mg once daily 1, 3, 9

Primary Aldosteronism

Starting dose: 12.5-25 mg once daily 4, 5 Target dose: Titrate gradually to 25-100 mg daily (maximum 400 mg for preoperative preparation) 4, 9

Hypertension

Starting dose: 25-100 mg daily in single or divided doses 9 Titration: Adjust at 2-week intervals; doses >100 mg/day provide minimal additional benefit 9, 10

Acne

Starting dose: 100 mg once daily in the evening 8 Range: 25-200 mg daily; higher doses increase side effects 8

Absolute Contraindications

  • Hyperkalemia (potassium >5.0 mEq/L at baseline) 2, 9
  • Severe renal impairment (creatinine >2.5 mg/dL in men, >2.0 mg/dL in women; eGFR <30 mL/min/1.73 m²) 2, 4
  • Addison's disease 8
  • Concomitant use of potassium supplements or potassium-sparing diuretics 11
  • Concurrent use of potent CYP3A4 inhibitors 11
  • Combined use of ACE inhibitor with ARB (increases hyperkalemia risk) 11, 1
  • Pregnancy (Category C; risk of feminization of male fetus) 8

Monitoring Protocol

Initial Phase (First 4-8 Weeks)

Check potassium and renal function:

  • Within 1 week of initiation 1, 2, 9
  • At 4 weeks 1, 2
  • At 1 and 4 weeks after any dose increase 1

Maintenance Phase

After achieving stable dose:

  • At 1,2,3, and 6 months 1
  • Every 6 months thereafter if stable 1, 12, 1

Special Populations

Young, healthy women treated for acne: Routine potassium monitoring is not required unless risk factors for hyperkalemia exist (renal disease, hypertension, heart disease, or concurrent medications like ACE inhibitors) 8.

Management of Adverse Effects

Hyperkalemia (Most Critical)

Potassium 5.5-5.9 mEq/L:

  • Halve the dose (e.g., 25 mg every other day) 1
  • Recheck potassium closely

Potassium ≥6.0 mEq/L:

  • Stop spironolactone immediately 1
  • Monitor blood chemistry closely
  • Initiate specific treatment for hyperkalemia
  • Consider restarting at reduced dose only after potassium <5.0 mEq/L for ≥72 hours 2

Worsening Renal Function

Creatinine rises to 220-310 µmol/L (2.5-3.5 mg/dL):

  • Halve the dose 1
  • Monitor closely

Creatinine >310 µmol/L (>3.5 mg/dL):

  • Stop spironolactone immediately 1
  • Specific treatment may be needed

Gynecomastia

Occurs in approximately 9-10% of men, dose-dependent (6.9% at <50 mg/day vs. 52% at >150 mg/day) 1, 4, 9. Usually reversible upon discontinuation. Consider switching to eplerenone if intolerable 1, 4.

Menstrual Irregularities

Occur in 15-30% of women, dose-dependent 8. Concomitant use of combined oral contraceptive or hormonal IUD minimizes this effect 8.

Other Common Side Effects

  • Breast tenderness (3-5%)
  • Dizziness (3-4%)
  • Nausea (2-4%)
  • Headache (2%)
  • Polyuria (1-2%)
  • Fatigue (1-2%) 8

Critical Clinical Pearls

Avoid triple therapy: Do not combine ACE inhibitor, ARB, and aldosterone antagonist due to severe hyperkalemia risk 13.

Discontinue potassium supplementation when initiating spironolactone, and counsel patients to avoid high-potassium foods and NSAIDs 2, 13.

Real-world hyperkalemia rates exceed trial data: Population studies show hyperkalemia rates of 11-24% in clinical practice versus 2% in trials, particularly in elderly patients and those with renal impairment 13. This mandates strict adherence to monitoring protocols.

Consistent food intake: Take with or without food, but maintain consistency 9.

Continue therapy even if asymptomatic: Patients who become asymptomatic or show LVEF improvement should continue spironolactone at the highest tolerated dose to prevent recurrence 3.

References

Guideline

primary aldosteronism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2025

Research

Spironolactone management of resistant hypertension.

The Annals of pharmacotherapy, 2010

Research

Spironolactone for hypertension.

The Cochrane database of systematic reviews, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.